Department of Paediatric Surgery, Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, and Inkosi Albert Luthuli Central Hospital, Durban, South Africa.
Pediatr Blood Cancer. 2014 Jun;61(6):987-9. doi: 10.1002/pbc.24948. Epub 2014 Jan 22.
Patients under age 4 with stage I favorable histology (FH) Wilms tumor have a reported survival advantage. Among children above 10 years, a poorer prognosis has been associated with a higher prevalence of diffuse anaplasia.
To determine if, in our practice, patients with Wilms tumors >8 years of age (stage II-V) have a poorer prognosis than those aged <8 years or <4 years.
Case-control study of 19 patients >8 years with Wilms tumor stages II-V who were identified from a cohort of 192 new patients (2002-2012). For each patient two controls were chosen matched for stage and histology, one 0-3 years and one 4-7 years. Neo-adjuvant chemotherapy was offered to all, combined with intensive supportive care. Postoperative treatment was determined by local stage and histology. OS and EFS at 5 years for the different age groups were compared.
Each age group contained 19 patients, of whom 6 had stage II tumors, 3 stage III, 8 stage IV, and 2 stage V. Histology was intermediate risk (IR) in 17 and high risk (HR) in 2. OS at 5 years was 80.8% and EFS was 79.2% for the whole group. No significant difference in outcome could be shown between age groups. Loss to follow up was 6/57 (11%).
The survival advantage of young age (<4 years) associated with stage I FH could not be demonstrated in higher stages. Age had no significant impact on prognosis although a trend to better outcome was seen in children <4 years.
患有 I 期良好组织学(FH)Wilms 瘤的 4 岁以下患者报告有生存优势。在 10 岁以上的儿童中,弥漫性间变的发生率较高与预后较差相关。
确定在我们的实践中,8 岁以上(II-V 期)患有 Wilms 瘤的患者是否比 8 岁以下或 4 岁以下的患者预后更差。
对 19 名 8 岁以上患有 Wilms 瘤 II-V 期的患者进行病例对照研究,这些患者是从 192 名新患者(2002-2012 年)队列中确定的。为每位患者选择了两名匹配分期和组织学的对照者,一名为 0-3 岁,一名为 4-7 岁。所有患者均接受新辅助化疗,并辅以强化支持治疗。术后治疗根据局部分期和组织学确定。比较不同年龄组的 5 年总生存率(OS)和无事件生存率(EFS)。
每个年龄组都包含 19 名患者,其中 6 名患有 II 期肿瘤,3 名患有 III 期肿瘤,8 名患有 IV 期肿瘤,2 名患有 V 期肿瘤。组织学为中危(IR)的有 17 例,高危(HR)的有 2 例。全组 5 年 OS 为 80.8%,EFS 为 79.2%。年龄组之间的结果无显著差异。失访率为 6/57(11%)。
I 期 FH 与年龄<4 岁相关的生存优势在较高分期中无法显示。尽管<4 岁的儿童预后较好,但年龄对预后无显著影响。